News about Market

ABL Bio Secures USD 40 Million Upfront, USD 15 Million Equity Investment From Eli Lilly

ABL Bio, a company focused on bispecific antibody technologies, announced that it will receive a USD 40 million upfront payment under a license, research, and collaboration agreement for its proprietary Grabody platform, along with a USD 15 million equity investment from Eli Lilly and Company.

Market | 29/12/2025 | By Darshana |  334

ABL Bio Receives Upfront Payment and Equity Investment from Lilly for Grabody Platform

ABL Bio has secured a total of USD 55 million in funding from Lilly, including a USD 40 million upfront payment and a USD 15 million equity investment, under a license, research and collaboration agreement to advance R&D and expand indications for its Grabody platform.

Market | 26/12/2025 | By News Bureau |  215

Windtree Therapeutics to Sell Cardiovascular Pipeline Assets

Windtree Therapeutics has agreed to sell its cardiovascular biotech pipeline assets to Seismic Pharmaceuticals under a deal that includes a potential USD 700,000 contingent payment, transfer of certain development payables, and Windtree retaining a 20 percent share of any future milestone, royalty, or global commercial revenue generated from the assets.

Market | 26/12/2025 | By News Bureau |  281

Aurobindo Pharma to Increase Stake in China JV for USD 5.12 Million

Aurobindo Pharma has announced plans to increase its shareholding in its China-based joint venture, Luoxin Aurovitas Pharma (Chengdu), by 20 percent through a cash investment of USD 5.12 million.

Market | 26/12/2025 | By Darshana |  391

Shionogi to Acquire Global Rights to RADICAVA ORS and IV RADICAVA

Shionogi plans to acquire the global rights and assets of Tanabe Pharma's RADICAVA ORS (edaravone) and IV RADICAVA, strengthening its rare disease portfolio, establishing a dedicated commercial platform in the U.S., and adding an estimated USD 700 million in annual global sales, with the transaction expected to be immediately accretive in FY26.

Market | 26/12/2025 | By News Bureau |  231

Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio

Sanofi has agreed to acquire Dynavax, strengthening its adult immunisation portfolio with an approved hepatitis B vaccine and a shingles vaccine candidate in phase I/II development. The deal combines Dynavax’s vaccine assets with Sanofi’s global development and commercial capabilities.

Market | 24/12/2025 | By News Bureau |  205

Vaccinex Secures USD 60 Million Financing for Phase IIb Alzheimer's Trial

Vaccinex Inc has entered into a USD 60 million revenue-sharing agreement with Pepinemab Development Venture (PDV), LP to finance an expanded Phase IIb clinical trial of its anti-SEMA4D antibody, pepinemab, for the treatment of Alzheimer’s disease.

Market | 24/12/2025 | By News Bureau |  190

Zydus Partners with Bioeq for US Commercialisation of Lucentis Biosimilar

Zydus has entered into a partnership with Bioeq to commercialise NUFYMCO, an interchangeable biosimilar to Lucentis, in the US market. Under the agreement, Bioeq will handle development, manufacturing, regulatory approval and product supply, while Zydus will oversee US commercialisation.

Market | 24/12/2025 | By News Bureau |  238

Biofabri and Bharat Biotech Sign Technology Transfer Deal for MTBVAC

Biofabri and Bharat Biotech have entered into a technology transfer agreement to enable end-to-end manufacturing of the MTBVAC tuberculosis vaccine candidate, supporting global efforts to expand access to new TB prevention options, particularly in high-burden, low- and middle-income countries.

Market | 24/12/2025 | By News Bureau |  353

Biocon Biologics Secures Global Rights to Hulio

The new agreement supersedes the existing collaboration agreement between Biocon Biologics and Fujifilm Kyowa Kirin Biologics (FKB) for biosimilar Adalimumab, under which Biocon Biologics only had commercialisation rights.

Market | 23/12/2025 | By News Bureau |  320